No abstract

No abstract

Successful treatment of eating disorders often includes drug therapy along with psychotherapy and nutritional counseling. Selective serotonin reuptake inhibitors are attractive agents for use in eating disorders due to their favorable side effect profiles. Currently, fluoxetine is the only FDA approved agent for treatment of bulimia nervosa; however, fluvoxamine has also been studied for use in this disorder. This review examines the evidence for the use of selective serotonin reuptake inhibitors in bulimia, and summarizes the pharmacokinetics, side effects, and drug interactions of selective serotonin reuptake inhibitors available in the United States.